Product Pipeline

iCeutica is internally developing a pipeline of products which it aims to launch itself, or with pharmaceutical marketing partners. Our goal is to use our proprietary SoluMatrix™ technology to enhance the therapeutic benefits, patient compliance and commercial attractiveness of a range of proven drugs in the fields of pain and inflammation, oncology, respiratory disease and migraine, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. We have proprietary product candidates in late and early stage development that address large market opportunities.

Our pain and inflammation portfolio is the most advanced with products recently successfully completing Phase 3 clinical trials and being prepared for registration filings in the coming months. Three SoluMatrix™ products in this therapeutic area have licensed out to an US-based pharmaceutical company, Iroko Pharmaceuticals. iCeutica retains commercialization rights to the balance of the pain and inflammation portfolio.

The portfolios of oncology, respiratory disease and migraine are being progressed towards the clinic and will be commercialized by iCeutica and its partners.